V212 + Placebo
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Herpes Zoster
Conditions
Herpes Zoster, Herpes Zoster-related Complications
Trial Timeline
Nov 2, 2007 → Jan 26, 2010
NCT ID
NCT00535236About V212 + Placebo
V212 + Placebo is a phase 1 stage product being developed by Merck for Herpes Zoster. The current trial status is completed. This product is registered under clinical trial identifier NCT00535236. Target conditions include Herpes Zoster, Herpes Zoster-related Complications.
What happened to similar drugs?
5 of 20 similar drugs in Herpes Zoster were approved
Approved (5) Terminated (1) Active (14)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01527383 | Phase 2 | Completed |
| NCT01254630 | Phase 3 | Completed |
| NCT00535236 | Phase 1 | Completed |
Competing Products
20 competing products in Herpes Zoster